AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Vestibular and Cortical Contributions to Transitions in Freezing of Gait in Parkinson's Disease

RecruitingNAAges 21 Years - 80 YearsAllUniversity of Minnesota
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Currently, there is a lack of comprehensive knowledge about the role of vestibulospinal drive and cortical activity during self-initiated movement transitions in older adults and people with PD (both with and without FOG). This set of experiments has two primary purposes: to (1) understand the pathological neurophysiology underlying freezing of gait (FOG) during movement transitions and FOG-inducing movements and (2) identify neurological biomarkers associated with FOG and FOG-inducing movements. To achieve this, the investigators will assess vestibular activity using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and assess cortical activity by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included). These experiments will investigate the vestibular (EVS Experiments) and cortical (EEG experiments

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Participants with Parkinson's disease (with and without Freezing of Gait) * Diagnosis of idiopathic PD. * Age 40-80 years. * Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters. Healthy Older Adults (Control participants) * Age 40-80 years (this group will be age- and sex-matched to the PD and FOG group). * Able to ambulate independently without the use of an assistive device (cane or walker). * Normal capacity to perform complex activities of daily living independently based on informant or physician report. Healthy Young Adults * Age 21-44 years (this group will be sex-matched to the PD and FOG group) * Able to ambulate independently without the use of an assistive device (cane or walker) Exclusion Criteria: Exclusion Criteria (for all participants): * Any musculoskeletal disorder that affects the ability to stand or walk. * History of musculoskeletal disorders that significantly affect movement of lower limbs. * Uncorrected visual impairment that may affect participation or performance in the study. * History of visual and/or vestibular conditions that may affect participation or performance in the study. * Meet criteria for dementia with Lewy bodies, Multiple Systems Atrophy, Alzheimer's disease, dementia diagnosis, or other neurodegenerative disorder other than Parkinson's disease. * History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury or other significant neurological disorders that may affect participation or performance in the study. * History of muscular conditions of the neck and back, including whiplash. * History of surgery on blood vessels, brain, or heart. * Unexplained, recurring headaches or concussion within the last six months. * Moderate to severe hearing impairment. * Subjects who are pregnant * Reduced capacity to consent. This will be assessed using a 2-stage process. Initially, participants will be tested using the University of California, San Diego, Brief Assessment of Capacity to Consent (UBACC). If the results of the UBACC are inconclusive the individual will be further tested using the MacArthur Competency Assessment Tool for Clinical Research (McCAT-CR). Additional exclusion criteria for EVS Experiments (Experiments 1 and 2): * History of motion sickness (as EVS can exacerbate motion sickness). * Intense physical exercise or consumption of alcohol in the 24 hours prior to any experiment that will include EVS testing. * Recent history of migraine headaches. * Intracranial metallic or magnetic devices. * Pacemaker or any implanted device. * Implanted deep brain stimulator or other neurosurgeries to treat PD. * Use of medications that can cause dizziness. Additional exclusion criteria for Control Participants: * Presence of parkinsonism or cognitive impairment (including dementia or mild cognitive impairment). * Active central nervous system, systemic, psychiatric conditions or use of psychoactive medication that would adversely affect cognitive, neuropsychiatric, motor, or autonomic functioning.
๐Ÿ’Š

What it tests

  • EVS and EEG
๐Ÿ“

Where

1 site
University of Minnesota, Movement Disorders Lab
Minneapolis, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy